Advances in Medical Sciences 63 (2018) 285–289

Contents lists available at ScienceDirect

Advances in Medical Sciences

journal homepage: www.elsevier.com/locate/advms

Review article

Interactions between the growth hormone and cytokines – A review

Mieczysław Szalecki[a,b], Anna Malinowska[a,*], Monika Prokop-Piotrkowska[a], Roman Janas[c]

[a] Department of Endocrinology and Diabetology, The Children's Memorial Health Institute, Warsaw, Poland
[b] Department of Medicine and Health Sciences, University of Jan Kochanowski (UJK), Kielce, Poland
[c] Department of Biochemistry, Radioimmunology and Experimental Medicine, The Children's Memorial Health Institute, Warsaw, Poland

ARTICLE INFO

Keywords:
Growth hormone
Proinflammatory interleukins
Anti-inflammatory interleukins
TNF-α

ABSTRACT

Numerous reports on the interactions between the immune and endocrine systems, especially growth hormone axis, can be found in the literature. Growth hormone acts mainly indirectly through insulin-like growth factor-1, which stimulates the growth and development processes, metabolism of lipids, proteins, and carbohydrates, and it also has a modulating effect on the cells of the immune system.

Several studies have been conducted on the influence of growth hormone therapy on the immunological parameters in children and adults with and without growth hormone deficiency. However, there have been no definite results and some of them have been even contradictory. Some studies have suggested that administration of growth hormone increases the production of tumor necrosis factor and certain pro- and anti-inflammatory cytokines; whereas other studies have demonstrated the lack of correlation between growth hormone and interleukins.

The aim of this paper was to evaluate the available literature on the interaction between growth hormone and TNF-α, pro-inflammatory (IL-1β, IL-2, IL-6) and anti-inflammatory (IL-4, IL-10) interleukins.

1. Introduction

Growth hormone (GH) stimulates the process of growth, differentiation and proliferation of cells. It influences bone mineralization, division and differentiation of myocytes, and metabolism of lipids, proteins and carbohydrates. GH acts mainly indirectly through the stimulation of synthesis and secretion of growth factors, including the most important one: insulin-like growth factor-1 (IGF-1).

Reports published during the last few decades suggest an interaction between the GH/IGF-1 axis and immune system [1,2,3]. Immune cells secrete numerous bioactive substances which affect neuroendocrinological processes but, on the other hand, the activity of the immune system is modulated by many endocrine factors [2,3]. A particular role is played by mast cells as an important compound in numerous immunological reactions. They are capable of storing and secreting many of the pro-inflammatory cytokines including: tumor necrosis factor (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6) and anti-inflammatory like: interleukin-4 (IL-4), interleukin-10 (IL-10) which affect cells of the endocrine system [4]. At present, a detailed interaction between the mast cells, growth hormone, and growth hormone axis is not well known.

It has been proven that GH participates in the development, regulation, and functioning of the immune system [5]. Experimental studies on mice with growth hormone deficiency (GHD) revealed the atrophy of thymus and spleen, a decreased number of hematopoietic cells and disorders of the cell-mediated immunity. Administration of GH to these mice resulted in a withdrawal of the immune system defects [5,6].

There are reports on cases of patients with coexisting GHD and primary immunologic deficiencies like X-linked agammaglobulinemia, decreased activity of natural killer (NK) lymphocytes and thymus hypoplasia [3,7–9].

The membrane receptor for GH belongs to the group of receptors for cytokines i.e. they are taking part in the activity of numerous hematopoietic growth factors, interleukins, interferons, and leptin. The presence of GH and IGF-1 receptors has been detected in the cells of the main lymphatic organs (thymus, bone marrow), peripheral lymphatic tissue and in the hematopoietic cells [5,6,10]. The influence of administration of exogenous GH on the immune system was a subject of several research projects [3,7,9,11]. It has been proven that GH, directly, as well as indirectly through the IGF-1, influences both cell-mediated and humoral immunity by increasing the production of antibodies by B lymphocytes, the activity of NK cells and macrophages, and by modulating functions of T lymphocytes and neutrophils [3,9]. Moreover, it increases the secretion of reactive oxygen forms in neutrophils, thus decreases the apoptosis of neutrophils, lymphocytes, and

* Corresponding author at: Department of Endocrinology and Diabetology, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, 04–730 Warsaw, Poland.
E-mail address: ammalinowska@op.pl (A. Malinowska).

https://doi.org/10.1016/j.advms.2018.03.001
Received 13 May 2017; Accepted 2 March 2018

monocytes [12].

The available data on the relationships of GH and cytokines in humans are limited. Moreover, studies conducted on this topic show contradictory results. Therefore, the aim of this study was to evaluate the available literature data on the interaction between the growth hormone and TNF-α and pro-inflammatory (IL-1β, IL-2, IL-6) and anti-inflammatory (IL-4, IL-10) interleukins.

2. Review

2.1. Cytokines

Cytokines are a large group of protein mediators which includes interleukins (ILs), colony-stimulating factors (CSFs), interferons (IFNs), tumor necrosis factors (TNFs) and growth factors. They are produced by many cells, including immune cells, fat tissue, mast cells, fibroblasts, endothelium cells, and keratinocytes. Their common feature is their pleiotropy, i.e. multidirectional activity. They can act on the cells which secrete them (autocrine action), on the adjacent cells (paracrine activity) or on the cells localized in different organs (endocrine activity) [13]. They present antagonistic, synergistic or complex activity depending on the type of target cell [14]. Cytokines play, among other roles, a role of the regulator of hematopoietic cells through their influence on survival, proliferation, differentiation, and homeostasis of lymphoid cells [3]. They play a major role in initiation and regulation of immunological response and inflammation [3]. Cytokines act on target cells via specific membrane receptors. Binding with receptors activates Janus kinase (JAK)/Signal Transducers and Activators of Transcription (STAT) signaling pathway [13].

2.2. Tumor necrosis factor (TNF-α)

Tumor necrosis factor (TNF-α) is a glycoprotein that is composed of 157 amino acids. TNF-α is secreted by activated monocytes and macrophages, and, to a lesser degree, by adipocytes, keratinocytes, fibroblasts, neutrophils, endothelium cells, mast cells and some of the lymphocytes. The strongest stimulus for TNF production are lipopolysaccharides (LPS) of bacterial cell walls [13]. TNF-α acts via receptors (TNF-R1 and TNF-R2) that are present on the surface of nearly all nucleated cells [13]. The activity of TNF-α is multidirectional. It is one of the main cytokines of inflammatory response since it participates in the acute phase response by stimulating the liver to produce acute phase proteins [13]. TNF-α activates transcription factor NF-κB which initiates the production of pro-inflammatory cytokines IL-6, TNF-α [15]. It takes part in the inhibition of development of neoplastic tumors and inhibition of replication of viruses [13,16]. Abrupt secretion of a considerable amount of TNF leads to the symptoms of shock, increase of catabolic hormones secretion and acute multiorgan insufficiency. Chronic secretion of small amounts of TNF causes weight loss, anorexia, catabolism of proteins and lipids, inflammatory changes in the inner walls of arteries that lead to the atherogenic changes [13]. TNF-α increases insulin resistance in peripheral tissues [16]. It is known that high concentration of TNF-α in chronic diseases deteriorates growth processes [17,18]. TNF-α seems to decrease the concentration of the IGF-1 due to diminishing expression of receptors for GH in the liver [19]. It causes resistance to IGF-1 in the growth plate limiting the process of chondrocytes' differentiation and accelerating their apoptosis [20]. Moreover, TNF-α inhibits the production of testosterone in the Leydig cells and the ovarian steroidogenesis [19].

2.3. Interleukin-1β (IL-1β)

Interleukin-1β (IL-1β) is a pro-inflammatory cytokine. It is synthesized by activated macrophages, monocytes, endothelial cells and adipocytes, mainly due to the presence of LPS and other products of microorganisms [13]. Its activity is triggered by binding to specific membrane receptor IL-R1 type I which is located on lymphocytes T, keratinocytes and fibroblasts. It can also bind to the IL-R1 type II receptor functioning as a so-called decoy receptor which does not cause any transduction signal [21,22]. IL-1β takes part in the inflammatory reactions, and processes of proliferation and differentiation of cells [23]. IL-1β stimulates cells to synthesis of the IL-2, IL-6, IL-8, TNF-α, IFN-γ, as well as its own synthesis, and adhesion molecules VCAM-1 (vascular cell adhesion molecule), ICAM-1 (intercellular adhesion molecule) [24,25]. It stimulates secretion of platelet activating factor (PAF) and platelet-derived growth factor [22]. An important effect of its activity is an increase in the synthesis of acute phase proteins in the liver [22,25].

IL-1β acts on the central nervous system causing a rise of body temperature, somnolence, and anorexia. It increases the production of corticotropin-releasing hormone (CRH) in the hypothalamus and adrenocorticotropic hormone (ACTH) in hypophysis, playing a major role in triggering the process of immunosuppression, mainly in order to protect against excessive, uncontrolled inflammatory reaction [22]. IL-1β can decrease insulin sensitivity playing a role in the pathogenesis of metabolic syndrome and diabetes type 2 [22]. In supraphysiological concentrations during chronic inflammatory diseases, it deteriorates growth due to a direct influence on growth plate, which is synergistic to TNF-**α** action [26]. It has been proven that IL-1β decreases serum concentration of IGF-I and ALS (acid-labile subunit) [19]. In studies performed on rats a decrease in the concentration of GH was observed after administering IL-1β [27]. Moreover, IL-β inhibits testosterone production in the Leydig cells and ovarian steroidogenesis [19].

2.4. Interleukin-2 (IL-2)

Interleukin-2 (IL-2) is a monomer build of 133 amino acids [23]. IL-2 is produced mainly by lymphocytes T helpers (Th), predominantly by Th1, and, to a lesser degree, by cytotoxic lymphocytes T [13]. Moreover, it is secreted in the intestinal mucous membrane, fat tissue and central nervous system [22]. Receptors for IL-2, built of three different chains: α, β and γ, are present on the activated lymphocytes T and B as well as on activated monocytes [13]. IL-2 is the activating factor for the regulatory T-cells and it can also stimulate proliferation of cytotoxic lymphocytes $CD8^+$ [22]. It serves as a growth factor for the T helper cells and NK cells and takes part in the production of different cytokines, among others: INF-γ, IL-6, lymphotoxins, IL-2 and GM-CSF [13]. IL-2 is one of the main mediators in autoimmune diseases and its increased blood concentration protects against autoimmunity [22]. First results of preclinical and clinical studies show a positive effect of low doses of IL-2 on the increase in regulatory lymphocytes T (Treg) in the therapy of type 1 diabetes and inflammatory diseases [28,29]. It is one of the most important cytokines participating in the inhibition of inflammatory reactions after antigen elimination [13]. Cells of the anterior lobe of pituitary gland have receptors for IL-2, which stimulate the secretion of GH and ACTH while used in anticancer therapy [27,30]. In the in vitro studies assessing the influence of IL-2 on the secretion of hormones from the anterior lobe of the pituitary gland the authors observed an increased concentration of PRL, TSH, and ACTH and, on the other hand, an inhibition of secretion of GH, LH, FSH [31].

2.5. Interleukin-6 (IL-6)

Interleukin-6 (IL-6) is known also as interferon β2, lymphocyte B stimulating factor or lymphocyte B differentiating factor [16,23]. It is produced mainly by monocytes and macrophages but also by lymphocytes T and B, fibroblasts, endothelium and adipocytes [13,16]. About 15–30% of circulating IL-6 is secreted by the adipose tissue [16,32]. It has been proven that skeletal muscles also produce IL-6 and its blood concentration rises during physical exercise [16,33]. The main factor that stimulates the secretion of IL-6 is IL-1, but also interferons, TNF,